In vitro activity of an evernimicin derivative, SCH27899, againts anaerobic bacteria and Propionibacterium acnes

Abstract

The in vitro activity of SCH27899, a novel oligosaccharide antimicrobial agent, was compared with those of representatives of six classes of antimicrobial agents (piperacillin, clarithromycin, clindamycin, vancomycin, sitafloxacin and metronidazole) against clinical isolates of anaerobic bacteria and Propionibacterium acnes. Against Peptostreptococcus spp. and Clostridium difficile, SCH27899 was the most potent (MIC90 < 0.125 mg/L) of the agents examined. Besides these Gram-positive anaerobes, SCH27899 showed a moderate level of activity against Prevotella bivia, Prevotella intermedia and Porphyromonas spp. (MIC90 ≤ 4mg/L).